Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alx Oncology Holdings, Inc. (ALXO)
:ALXO
RESEARCH TOOLSreports
ALXO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.96 - $17.83
Previous CloseN/A
Volume579.15K
Average Volume (3M)1.01M
Market Cap
$59.07M
Enterprise Value-$35.31M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Mar 06, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding52,743,103
10 Day Avg. Volume563,863
30 Day Avg. Volume1,005,825
Standard Deviation0.30
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.24
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$3.33Price Target Upside197.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
ALX Oncology Holdings News
PremiumCompany Announcements
ALX Oncology Strengthens Leadership with Key Appointments
PremiumCompany Announcements
ALX Oncology Adopts 2025 Inducement Equity Plan
---
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceEvorpacept + TRP had an ORR of 59.1% in the fresh HER2+ biopsy patient population, significantly outperforming the TRP control arm.
Combination Therapy PotentialThe combination therapy of evorpacept and zanidatamab was well-tolerated, with a low percentage of patients experiencing serious adverse effects.
Solid Tumor ThesisPositive clinical data update strengthens solid tumor thesis for Evorpacept.
Bears Say
Financial SustainabilityALX Oncology has approximately 1.3 years of cash left, which may raise concerns about the company's financial sustainability.
Market SkepticismThe short interest in ALX Oncology is relatively high, indicating that a significant portion of the market may be betting against the company's stock performance.
Phase II Data ExpectationsFull Phase II data in gastric failed to meet expectations and the efficacy had come way down in H2 of the study post interim.
---
Ownership Overview
3.48% Insiders
10.13% Mutual Funds
39.28% Other Institutional Investors
40.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALXO FAQ
What was Alx Oncology Holdings, Inc.’s price range in the past 12 months?
Alx Oncology Holdings, Inc. lowest stock price was $0.96 and its highest was $17.82 in the past 12 months.
What is Alx Oncology Holdings, Inc.’s market cap?
Alx Oncology Holdings, Inc.’s market cap is $59.07M.
When is Alx Oncology Holdings, Inc.’s upcoming earnings report date?
Alx Oncology Holdings, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 12 days.
How were Alx Oncology Holdings, Inc.’s earnings last quarter?
Alx Oncology Holdings, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.78 by $0.2.
Is Alx Oncology Holdings, Inc. overvalued?
According to Wall Street analysts Alx Oncology Holdings, Inc.’s price is currently Undervalued.
Does Alx Oncology Holdings, Inc. pay dividends?
Alx Oncology Holdings, Inc. does not currently pay dividends.
What is Alx Oncology Holdings, Inc.’s EPS estimate?
Alx Oncology Holdings, Inc.’s EPS estimate is -0.67.
How many shares outstanding does Alx Oncology Holdings, Inc. have?
Alx Oncology Holdings, Inc. has 52,743,103 shares outstanding.
What happened to Alx Oncology Holdings, Inc.’s price movement after its last earnings report?
Alx Oncology Holdings, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.78. Following the earnings report the stock price went down -3.974%.
Which hedge fund is a major shareholder of Alx Oncology Holdings, Inc.?
Currently, no hedge funds are holding shares in ALXO
---
ALX Oncology Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.33 (197.32% Upside)
$3.33 (197.32% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $22.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.10%
12-Months-Change
Fundamentals
Return on Equity
-98.94%
Trailing 12-Months
Asset Growth
-15.63%
Trailing 12-Months
Company Description
Alx Oncology Holdings, Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.
---
ALXO Stock 12 Month Forecast
Average Price Target
$3.33
▲(197.32% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
IGM Biosciences
―
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
4/17 ratings generated profit
1 Year Average Return
-25.73%
reiterated a buy rating 29 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -25.73% per trade.
---